Search results for "Phage"

Microglia and α-synuclein implication in Parkinson's disease

2011

Age-related neurodegenerative disorders like Parkinson’s disease take an enormous toll on individuals and on society. Despite extensive efforts, Parkinson’s disease remains incurable and only very limited treatments exist. Indeed, Parkinson’s pathogenesis is still not clear and research on its molecular mechanisms is ongoing. In this study, we focused our interest on two abnormal events occurring in Parkinson’s patients, namely α-synuclein aggregation and microglial activation. We first investigated α-synuclein and its abnormal polymerisation. For this purpose, we developed novel methods, which allowed the in vitro production of different types of α-synuclein oligomers. Using highly sensiti…

Les sarcophages de pierre du site d’Escolives-Sainte-Camille. Étude typologique et pétrographique

2002

National audience

Les sarcophages du haut Moyen Âge en Bourgogne du nord – Approches méthodologiques, premiers résultats et réflexions

2001

International audience

Eglise de Saint-Martin-au-Val, Chartres (Eure-et-Loir) - Etude pétrographique des sarcophages mérovingiens découverts dans le sondage Lecocq de 1862

2014

Eglise de Saint-Martin-au-Val, Chartres (Eure-et-Loir). Etude pétrographique des sarcophages SAR.8267, SAR.8510, SAR.8511, SAR.8579 - Rapport d'étude

2016

Eglise de Saint-Martin-au-Val, Chartres (Eure-et-Loir). Etude pétrographique du sarcophage SAR.8407

2015

Les sarcophages en grès dans le nord de l’Auvergne et la région Centre, état des recherches

2009

International audience

Projet collectif de recherche. Les sarcophages en grès de la bordure septentrionale du Massif Central : production, diffusion, utilisations et remplo…

2008

International audience; Le projet collectif de recherche sur les sarcophages en grès de la bordure septentrionale du Massif central a été engagé en 2004, suite à une table ronde qui a eu lieu en 2003 à l’université de Clermont-Ferrand 1, lors de laquelle le constat a été fait que ce thème souffrait d’un manque d’étude récente. Un groupe de quatre chercheurs – aux spécialités complémentaires : S. Liegard (INRAP), F. Henrion (CEM), S. Büttner (CEM) et A. Fourvel (INRAP) – s’est alors formé pour mener à bien ce projet, dont le premier volet s’est déroulé sur quatre années, de 2004 à 2007.

Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets?

2017

Introduction: Macrophage activation syndrome (MAS) is a severe, hyperinflammatory life-threatening syndrome, generally complicating different rheumatic diseases. Despite the severity of the disease, little is known about the pathogenic mechanisms and, thus, possible targeted therapies in the management of these patients. Areas covered: In this review, we aimed to update the current pathogenic knowledge of MAS, during rheumatic diseases, focusing mainly on immunologic abnormalities and on new possible therapeutic strategies. Expert commentary: The difficult pathogenic scenario of MAS, in which genetic defects, predisposing diseases, and triggers are mixed together with the high mortality rat…

Phage therapy

2013

Bacteriophage therapy, the use of viruses that infect bacteria as antimicrobials, has been championed as a promising alternative to conventional antibiotics. Although in the laboratory bacterial resistance against phages arises rapidly, resistance so far has been an only minor problem for the effectiveness of phage therapy. Resistance to antibiotics, however, has become a major issue after decades of extensive use. Should we expect similar problems after long-term use of phages as antimicrobials? Like antibiotics, phages are often noted to be drivers of bacterial evolution. Should we expect phage-treated pathogens to develop a general resistance to phages over time, a resistance against whi…